Improved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence

Lauren S. Prescott, Lisa M. Kidin, Rebecca L. Downs, David J. Cleveland, Ginger L. Wilson, Mark F. Munsell, Alma Y. DeJesus, Katherine E. Cain, Pedro T. Ramirez, Michael H. Kroll, Charles F. Levenback, Kathleen M. Schmeler

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: National guidelines recommend prophylactic anticoagulation for all hospitalized patients with cancer to prevent hospital-acquired venous thromboembolism (VTE). However, adherence to these evidence-based recommended practice patterns remains low.We performed a quality improvement (QI) project to increase VTE pharmacologic prophylaxis rates among patients with gynecologic malignancies hospitalized for nonsurgical indications and evaluated the resulting effect on rates of development of VTE. Materials and Methods: In June 2011, departmental VTE practice guidelines were implemented for patients with gynecologic malignancies who were hospitalized for nonsurgical indications. A standardized VTE prophylaxis module was added to the admission electronic order sets. Outcome measures included number of admissions receiving VTE pharmacologic prophylaxis within 24 hours of admission; and number of potentially preventable hospitalacquired VTEs diagnosed within 30 and 90 days of discharge. Outcomes were compared between a preguideline implementation cohort (n = 99), a postguideline implementation cohort (n = 127), and a sustainability cohort assessed 2 years after implementation (n = 109). Patients were excluded if upon admission they had a VTE, were considered low risk for VTE, or had a documented contraindication to pharmacologic prophylaxis. Results: Administration of pharmacologic prophylaxis within 24 hours of admission increased from 20.8% to 88.2% immediately following the implementation of guidelines, but declined to 71.8% in our sustainability cohort (P G 0.001). There was no difference in VTE incidence among the 3 cohorts [n = 2 (4.2%) vs n = 3 (3.9%) vs n = 3 (4.2%), respectively; P = 1.00]. Conclusions: Our QI project improved pharmacologic VTE prophylaxis rates. A small decrease in prophylaxis during the subsequent 2 years suggests a need for continued surveillance to optimize QI initiatives. Despite increased adherence to guidelines, VTE rates did not decline in this high-risk population.

Original languageEnglish (US)
Pages (from-to)152-159
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2015

Keywords

  • Guidelines
  • Gynecologic cancer
  • Patient safety
  • Quality improvement
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Improved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence'. Together they form a unique fingerprint.

Cite this